Stomach Cancer Clinical Trials
Gastric Cancer
Learn More About Stomach Cancer
For general information on stomach cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| A001 | Gastric Cancer | A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies | Immunotherapy | CDH17 targeting IO. | Closed | Arbele Pty Ltd | NCT05411133/a> | Enquire Now |
| MTX-TROP2-302 | Gastric Cancer | MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors | Immunotherapy | TROP2 targeting. Low volume disease only. | Closed | Myeloid Therapeutics | NCT05969041/a> | Enquire Now |
| PTT-4256-01 | Gastric Cancer | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849/a> | Enquire Now |
| AMT-116-01 | Gastric Cancer | First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti-CD44v9 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics Inc. | NCT05725291/a> | Enquire Now |
| CP-IVX001 | Gastric Cancer | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487/a> | Enquire Now |
| SSGJ-709-101 | Gastric Cancer | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors | Immunotherapy | Anti-PD-1 and anti-LAG-3 bispecific antibody | Open - Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07016490/a> | Enquire Now |